Blue Trust Inc. Sells 679 Shares of Solventum Corporation $SOLV

Blue Trust Inc. decreased its stake in shares of Solventum Corporation (NYSE:SOLV) by 8.9% in the second quarter, HoldingsChannel reports. The institutional investor owned 6,922 shares of the company’s stock after selling 679 shares during the period. Blue Trust Inc.’s holdings in Solventum were worth $525,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chelsea Counsel Co. lifted its holdings in Solventum by 720.7% during the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock valued at $804,000 after buying an additional 9,304 shares in the last quarter. ST Germain D J Co. Inc. lifted its holdings in Solventum by 84.6% during the 2nd quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock valued at $63,000 after buying an additional 378 shares in the last quarter. CX Institutional lifted its holdings in Solventum by 11.7% during the 2nd quarter. CX Institutional now owns 2,376 shares of the company’s stock valued at $180,000 after buying an additional 249 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in Solventum during the 2nd quarter valued at about $71,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in Solventum by 0.9% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock valued at $4,832,000 after buying an additional 583 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV opened at $70.53 on Monday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The firm has a market cap of $12.23 billion, a PE ratio of 32.65, a P/E/G ratio of 2.87 and a beta of 0.50. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92. The stock has a fifty day moving average price of $72.75 and a 200-day moving average price of $72.08.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the previous year, the business earned $1.56 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on SOLV. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective for the company in a report on Tuesday, July 1st. Piper Sandler reissued an “overweight” rating and set a $94.00 price objective (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Jefferies Financial Group began coverage on Solventum in a research report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Solventum currently has a consensus rating of “Hold” and an average target price of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.